MADRIGAL PHARMACEUTICALS, INC.

MDGL 10-Q · Q1 2026
API behind this page

MDGL Q1 2026 request

Playground key active
Request URL /api/financials?ticker=MDGL&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 311,337 137,250 +126.8%
Show Business Segments breakouts
Reportable Segment 311,337 137,250 +126.8%
Operating Costs And Expenses 26,847 4,513 +494.9%
Research And Development Expense Excluding Acquired In Process Cost 108,692 44,172 +146.1%
Show Counterparty Name breakouts
Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB 48.3 — —
Selling, General & Administrative 268,521 167,876 +60.0%
Operating Expenses 404,060 216,561 +86.6%
Operating Income -92,723 -79,311 -16.9%
Interest Income 8,243 9,370 -12.0%
Interest Expense -7,819 -3,297 -137.2%
Other Non-Operating Income (Expense) -2,092 — —
Net Income -94,391 -73,238 -28.9%
Show Business Segments breakouts
Reportable Segment -94,391 -73,238 -28.9%
Show Equity Components breakouts
Retained Earnings -94,391 -73,238 -28.9%
EPS (Basic) -3.25 -2.61 -24.5%
EPS (Diluted) -3.25 -2.61 -24.5%
Wtd Avg Shares (Basic) 29,032,422 28,085,234 +3.4%
Wtd Avg Shares (Diluted) 29,032,422 28,085,234 +3.4%
Cost of Revenue (Q) — — —
Show Business Segments breakouts
Reportable Segment -26,847 -4,513 -494.9%
Comprehensive Income -94,182 -73,317 -28.5%
Other Comprehensive Income 209 -79 +364.6%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 209 -79 +364.6%
Labor And Related Expense (Q) — — —
Show Business Segments breakouts
Reportable Segment · Research And Development Expense -15,097 -9,035 -67.1%
Reportable Segment · Selling General And Administrative Expenses -83,605 -48,361 -72.9%
Professional Fees (Q) — — —
Show Business Segments breakouts
Reportable Segment · Research And Development Expense -84,547 -28,797 -193.6%
Reportable Segment · Selling General And Administrative Expenses -131,252 -88,014 -49.1%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 227,033 183,646 +23.6%
Restricted Cash Current 5,155 — —
Available For Sale Securities Debt Securities Current 585,738 659,422 -11.2%
Accounts Receivable 187,356 61,428 +205.0%
Inventory 112,070 55,241 +102.9%
Prepaid Expenses & Other Current Assets 64,955 — —
Show Counterparty Name breakouts
Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB 11.7 — —
Total Current Assets 1,182,307 987,979 +19.7%
Non-Current Assets
Property, Plant & Equipment 8,035 1,901 +322.7%
Intangible Assets 7,284 4,639 +57.0%
Operating Lease Right-of-Use Assets 6,203 — —
Show Geography breakouts
West Conshohocken, Pennsylvania 4 — —
Other Non-Current Assets 23,498 — —
Total Assets 1,227,327 996,629 +23.1%
Current Liabilities
Accounts Payable 60,801 42,056 +44.6%
Accrued Liabilities 275,761 124,165 +122.1%
Operating Lease Liability Current 1,697 1,016 +67.0%
Total Current Liabilities 338,259 167,237 +102.3%
Non-Current Liabilities
Long-Term Debt 340,330 118,005 +188.4%
Operating Lease Liabilities 5,284 750 +604.5%
Liabilities Noncurrent 345,614 118,755 +191.0%
Total Liabilities 683,873 285,992 +139.1%
Long-Term Debt 340,330 — —
Show Debt Instrument breakouts
The Financing Agreement · Secured Debt 350 — —
Stockholders' Equity
Common Stock 2 2 0.0%
Additional Paid In Capital Common Stock 2,727,227 2,585,666 +5.5%
Accumulated Other Comprehensive Income 1,082 389 +178.1%
Retained Earnings -2,184,857 -1,875,420 -16.5%
Total Stockholders' Equity 543,454 710,637 -23.5%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 1,082 389 +178.1%
Additional Paid In Capital 2,727,227 2,585,666 +5.5%
Common Stock 2 2 0.0%
Retained Earnings -2,184,857 -1,875,420 -16.5%
Total Liabilities & Equity 1,227,327 996,629 +23.1%
Preferred Stock Shares Issued 2,369,797 — —
Preferred Stock Shares Outstanding 2,369,797 — —
Show Equity Components breakouts
Preferred Stock 2,369,797 2,369,797 0.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Stock-Based Compensation 34,018 20,931 +62.5%
Depreciation & Amortization 386 379 +1.8%
Amortization Of Financing Costs And Discounts 449 436 +3.0%
Operating Lease Right Of Use Asset Periodic Reduction Increase 408 56 +628.6%
Other Non-Cash Items -2,440 — —
Change in Accounts Receivable -52,880 -7,606 -595.2%
Change in Prepaid & Other Assets -40,649 -9,456 -329.9%
Change in Inventory -22,187 -21,173 -4.8%
Increase Decrease In Accounts Payable Trade 3,584 -1,543 +332.3%
Increase Decrease In Accrued Liabilities 4,287 -530 +908.9%
Increase Decrease In Accrued Interest Net Of Interest Received 1,980 2,853 -30.6%
Net Cash from Operations -167,435 -88,891 -88.4%
Investing Activities
Purchases of Investments -157,829 -130,812 -20.7%
Proceeds From Sale And Maturity Of Available For Sale Securities 353,869 294,690 +20.1%
Capital Expenditures -3,849 — —
Net Cash from Investing 192,191 163,878 +17.3%
Financing Activities
Proceeds From Stock Options Exercised 2,329 8,640 -73.0%
Show Award Type breakouts
Employee Stock Option 2.3 8.6 -73.3%
Net Cash from Financing 2,329 8,640 -73.0%
Supplemental
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 1,672 — —
Unpaid Capital Expenditures 2,979 — —
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 1,320 — —
Net Change in Cash 28,405 83,627 -66.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 232,188 188,646 +23.1%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key